Milestone Pharmaceuticals Shares Gain After Arrhythmia Treatment Receives FDA Approval
By Connor Hart
Shares of Milestone Pharmaceuticals climbed after the company said its first commercial product, Cardamyst nasal spray, was approved by the Food and Drug Administration to treat paroxysmal supraventricular tachycardia, or PSVT.
PSVT is a type of arrhythmia that causes a fast heart rate and other symptoms, such as chest discomfort, heart palpitations, shortness of breath and dizziness.
The stock jumped 22%, to $2.94, in premarket trading Monday. Through Friday's close, shares are up nearly 35% over the past year.
Cardamyst is expected to be available in retail pharmacies in the first quarter of 2026, Milestone said late Friday, adding that the approval marks the first time that more than two million Americans with PSVT will have a rapid-acting treatment option that can be self-administered outside of an emergency facility or other healthcare setting.
"The FDA approval of Cardamyst is a watershed moment for Milestone and a gratifying event for our team members, patients, clinical investigators and health care providers who participated in the development program," Chief Executive Joseph Oliveto said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 15, 2025 09:35 ET (14:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States